Miyake Lab Home ¨ Publication List ¨ before 2000

 Pubication List: Original articles

before 2000

1) Miyake S, Yagita H, Maruyama T, Hashimoto H, Miyasaka N Okumura K: ƒΐ1 Integrin-mediated interaction with extracellular matrix protein regulates cytokine gene expression in synovial fluid cells of rheumatoid arthritis patients. J Exp Med 177: 863-868, 1993

2) Maruyama T, Saito I, Miyake S, Hashimoto H, Sato K, Yagita H, Okumura K Miyasaka N: A possible role of two hydrophobic amino acids in antigen recognition by synovial T cells in rheumatoid arthritis. Eur J Immunol 23:2059-2065, 1993

3) Miyake S, Sakurai T, Okumura K, Yagita H: Identification of collagen and laminin receptor integrins on murine lymphocytes. Eur J Immunol 24: 2000-2005, 1994

4) Panchamoorthy G, Fukazawa T, Miyake S, Soltoff S, Reedquist K, Druker B, Shoelson S, Cantley L, Band H: p120cbl is major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of Phosphatidylinositol 3-kinase. J Biol Chem 271:3187-3194, 1996

5) Miyake S*, Fukazawa T*, Band V, Band H: Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem 271:14554-14559, 1996 * Eaqual contribution.

6) Lupher ML, Reedquist KA, Miyake S, Langdon WY Band H: A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J Biol Chem 271:24063-24068, 1996

7) Tokano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, Yagita H, Takasaki Y, Okumura K, Hashimoto H: Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol 16:261-265, 1996

8) Bonita D, Miyake S, Lupher ML, Langdon WY, Band H:Phophotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha singaling cascade by transforming mutants of Cbl:Implications for Cbl's function and oncogenicity. Mol Cell Biol 17:4597-4610, 1997

9) Miyake S, Lupher ML, Andoniou CE, Lill NL, Ota A, Douillard P, Rao N, Band H:The Cbl proto-oncogene product: From an enigmatic oncogene to center-stage of singnal transduction. Critical Reviews on Oncogenesis 8:189-218, 1997

10) Miyake S, Lupher ML, Druker B, Band H: The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet derived growth factor receptor ƒΏ. Proc Natl Acad Sci USA 95:7927-7932, 1998

11) Lupher ML, Rao N, Andoniou CE, Miyake S, Band H: Cbl-mediated negative regulation of the Syk tyrosine kinase: A critical role for Cbl PTB domain binding to SykpY323. J Biol Chem 273:35273-35281, 1998

12) Lupher, ML, Andoniou CE, Bonita D, Miyake S, Band H: Molecules in Focus: The c-Cbl oncoprotein. Int J Biochem Cell Biol 30:439-444, 1998

13) Miyake S, Mullane KP, Douillard P, Band H: Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. J Biol Chem 274:16619-16628, 1999

14) Lill NL, Douillard P, Awwad R, Ota S, Lupher ML, Miyake S, Meissner NS, Hsu V, Band H: The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem 275:367-377, 2000

15) Rosenkranz S, Ikuno Y, Leong FL, Klinghoffer RA, Miyake S, Band H, Kazlauskas A: Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem 275:9620-9627, 2000

Miyake Lab, Dep of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry

4-1-1 Ogawa-higashimachi, Kodaira, Tokyo, 187-8502 Japan@@Tel: 042-341-2711@Fax: 042-346-1753
Copyright (C) 2010 Miyake Lab. All Rights Reserved.